Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance database
Seminars in Arthritis and Rheumatism Sep 02, 2017
Lee MY, et al. – An analysis was performed to determine the persistence of adalimumab, etanercept, infliximab, or abatacept as first– and subsequent–line treatment for rheumatoid arthritis in the South Korean. When used as first–line treatment, adalimumab, etanercept, and infliximab had similar levels of persistence during the 1–year after treatment initiation. Whereas, when used as a subsequent–line treatment, etanercept and abatacept had higher persistence than infliximab or adalimumab. Persistence could be helpful when selecting the subsequent–line biologic treatment for patients with rheumatoid arthritis in South Korea.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries